• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Corvus Pharmaceuticals Inc. (Amendment)

    5/13/24 4:52:14 PM ET
    $CRVS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRVS alert in real time by email
    SC 13G/A 1 d11045799_13g-a.htm

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 1)*

     

     

    Corvus Pharmaceuticals, Inc.
    (Name of Issuer)

     

     

    Common Stock, par value $0.0001 per share
    (Title of Class of Securities)

     

     

    221015100
    (CUSIP Number)

     

     

    May 1, 2024
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    [_] Rule 13d-1(b)

     

    [X] Rule 13d-1(c)

     

    [_] Rule 13d-1(d)

     

    __________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

     


    CUSIP No
    221015100    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Samlyn Capital, LLC  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      6,267,984*  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      6,267,984*  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      6,267,984*  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.99%*  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IA, OO  

    * Samlyn Capital, LLC (“Samlyn Capital”) is deemed to beneficially own warrants of the issuer (“Warrants”) that are directly owned by certain of Samlyn Capital’s investment advisory clients (such clients, the “Samlyn Clients”). The Warrants, each of which converts into shares of Common Stock on a 1 to 1 basis, are subject to a blocker provision that prevents each Samlyn Client from exercising the Warrants if it or any of its affiliates, including Samlyn Capital, would be more than a 9.99% beneficial owner of the issuer’s outstanding Common Stock following such exercise (the “Blocker Provision”). Accordingly, the number of shares of Common Stock and the percentage of the issuer’s outstanding Common Stock deemed beneficially owned by Samlyn Capital have been adjusted to account for: (i) the maximum amount of Warrants that the Samlyn Clients can collectively exercise, giving effect to the Blocker Provision; and (ii) the additional shares of Common Stock that would be issued by the issuer to the Samlyn Clients in connection with full exercise of the Warrants by the Samlyn Clients, giving effect to the Blocker Provision.

     
     

     

    CUSIP No 221015100    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Samlyn, LP  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      Delaware  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      6,267,984*  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      6,267,984*  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      6,267,984*  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.99%*  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      PN  

    * Samlyn, LP is deemed to beneficially own warrants of the issuer (“Warrants”) that are directly owned by certain of Samlyn Capital, LLC’s (“Samlyn Capital”) investment advisory clients (such clients, the “Samlyn Clients”). The Warrants, each of which converts into shares of Common Stock on a 1 to 1 basis, are subject to a blocker provision that prevents each Samlyn Client from exercising the Warrants if it or any of its affiliates, including Samlyn, LP, would be more than a 9.99% beneficial owner of the issuer’s outstanding Common Stock following such exercise (the “Blocker Provision”). Accordingly, the number of shares of Common Stock and the percentage of the issuer’s outstanding Common Stock deemed beneficially owned by Samlyn, LP have been adjusted to account for: (i) the maximum amount of Warrants that the Samlyn Clients can collectively exercise, giving effect to the Blocker Provision; and (ii) the additional shares of Common Stock that would be issued by the issuer to the Samlyn Clients in connection with full exercise of the Warrants by the Samlyn Clients, giving effect to the Blocker Provision.

     
     

     

    CUSIP No 221015100    

     

    1. NAME OF REPORTING PERSONS  
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)  
         
      Robert Pohly  
         
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
        (a)  [_]
        (b)  [_]
         
    3. SEC USE ONLY  
         
         
    4. CITIZENSHIP OR PLACE OF ORGANIZATION  
         
      United States of America  
         
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
         
    5. SOLE VOTING POWER  
         
      0  
         
    6. SHARED VOTING POWER  
         
      6,267,984*  
         
    7. SOLE DISPOSITIVE POWER  
         
      0  
         
    8. SHARED DISPOSITIVE POWER  
         
      6,267,984*  
         
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
         
      6,267,984*  
         
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)  
        [_]
         
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)  
         
      9.99%*  
         
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)  
         
      IN, HC  

     

    * Robert Pohly is deemed to beneficially own warrants of the issuer (“Warrants”) that are directly owned by certain of Samlyn Capital, LLC’s (“Samlyn Capital”) investment advisory clients (such clients, the “Samlyn Clients”). The Warrants, each of which converts into shares of Common Stock on a 1 to 1 basis, are subject to a blocker provision that prevents each Samlyn Client from exercising the Warrants if it or any of its affiliates, including Robert Pohly, would be more than a 9.99% beneficial owner of the issuer’s outstanding Common Stock following such exercise (the “Blocker Provision”). Accordingly, the number of shares of Common Stock and the percentage of the issuer’s outstanding Common Stock deemed beneficially owned by Robert Pohly have been adjusted to account for: (i) the maximum amount of Warrants that the Samlyn Clients can collectively exercise, giving effect to the Blocker Provision; and (ii) the additional shares of Common Stock that would be issued by the issuer to the Samlyn Clients in connection with full exercise of the Warrants by the Samlyn Clients, giving effect to the Blocker Provision.

     
     

     

    CUSIP No 221015100    

     

    Item 1. (a). Name of Issuer:  
           
        Corvus Pharmaceuticals, Inc.  
       

     

     

     
      (b). Address of Issuer's Principal Executive Offices:  
           
       

    863 Mitten Road, Suite 102

    Burlingame, California 94010

    United States of America

     
           
    Item 2. (a). Name of Person Filing:  
           
       

    Samlyn Capital, LLC

    Samlyn, LP

    Robert Pohly

     
       

     

     

     
      (b). Address of Principal Business Office, or if None, Residence:  
           
       

    Samlyn Capital, LLC

    500 Park Avenue, 2nd Floor

    New York, New York 10022

    United States of America

     

    Samlyn, LP

    c/o Samlyn Capital, LLC

    500 Park Avenue, 2nd Floor

    New York, New York 10022

    United States of America

     

    Robert Pohly

    c/o Samlyn Capital, LLC

    500 Park Avenue, 2nd Floor

    New York, New York 10022

    United States of America

     

     

      (c). Citizenship:  
           
       

    Samlyn Capital, LLC – Delaware

    Samlyn, LP – Delaware

    Robert Pohly – United States of America

     
       

     

     

     
      (d).   Title of Class of Securities:  
           
        Common Stock, par value $0.0001 per share  
       

     

     

     
      (e). CUSIP Number:  
           
        221015100  
     
     

     


    Item 3.
    If This Statement is filed pursuant to ss.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a

     

         
      (a) [_] Broker or dealer registered under Section 15 of the Exchange Act (15 U.S.C. 78c).
           
      (b) [_] Bank as defined in Section 3(a)(6) of the Exchange Act (15 U.S.C. 78c).
           
      (c) [_] Insurance company as defined in Section 3(a)(19) of the Exchange Act (15 U.S.C. 78c).
           
      (d) [_] Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).
           
      (e) [_] An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
           
      (f) [_] An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
           
      (g) [_] A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
           
      (h) [_] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C.1813);
           
      (i) [_] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
      (j)   [_]

    Group, in accordance with s.240.13d-1(b)(1)(ii)(J).

     

     

    Item 4. Ownership.
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
       
      (a) Amount beneficially owned:
         
       

    Samlyn Capital, LLC – 6,267,984

    Samlyn, LP – 6,267,984

    Robert Pohly – 6,267,984

         
      (b) Percent of class:
         
       

    Samlyn Capital, LLC – 9.99%

    Samlyn, LP – 9.99%

    Robert Pohly – 9.99%

     

      (c) Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote
         

     

    Samlyn Capital, LLC – 0

    Samlyn, LP – 0

    Robert Pohly – 0

     

        (ii) Shared power to vote or to direct the vote
         

     

    Samlyn Capital, LLC – 6,267,984

    Samlyn, LP – 6,267,984

    Robert Pohly – 6,267,984

           
        (iii) Sole power to dispose or to direct the disposition of
         

     

    Samlyn Capital, LLC – 0

    Samlyn, LP – 0

    Robert Pohly – 0

           
        (iv) Shared power to dispose or to direct the disposition of
         

     

    Samlyn Capital, LLC – 6,267,984

    Samlyn, LP – 6,267,984

    Robert Pohly – 6,267,984

     

     
     

     

     

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [_].
     
      N/A
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than five percent of the class, such person should be identified.  A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
     
      All of the securities reported in this Schedule 13G are directly owned by advisory clients of Samlyn Capital, LLC.  None of those advisory clients may be deemed to beneficially own more than 5% of the Common Stock, par value $0.0001 per share.
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.
       
      If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary.  If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      Please see Exhibit B attached hereto.

     
    Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group.  If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A
       
    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity.  See Item 5.
       
      N/A

     

     

    Item 10. Certification.
     
        By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a–11.
         
     
     

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

      May 13, 2024
      (Date)
       
         
      SAMLYN CAPITAL, LLC*
         
      By: Samlyn, LP, its sole member
         
      By: Samlyn GP, LLC, its general partner
         
      By: /s/ Robert Pohly
        Name:  Robert Pohly
        Title:  Managing Member
         
         
      SAMLYN, LP*
         
      By: Samlyn GP, LLC, its general partner
         
      By: /s/ Robert Pohly
        Name:  Robert Pohly
        Title:  Managing Member
         
         
      ROBERT POHLY*
         
      By: /s/ Robert Pohly
         

     

    * This Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative's authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     
     

    Exhibit A

     

    AGREEMENT

     

    The undersigned agree that this Amendment No. 1 to Schedule 13G dated May 13, 2024 relating to the Common Stock, par value $0.0001 per share, of Corvus Pharmaceuticals, Inc. shall be filed on behalf of the undersigned.

         
      SAMLYN CAPITAL, LLC
         
      By: Samlyn, LP, its sole member
         
      By: Samlyn GP, LLC, its general partner
         
      By: /s/ Robert Pohly
        Name:  Robert Pohly
        Title:  Managing Member
         
         
      SAMLYN, LP
         
      By: Samlyn GP, LLC, its general partner
         
      By: /s/ Robert Pohly
        Name:  Robert Pohly
        Title:  Managing Member
         
         
      ROBERT POHLY
         
      By: /s/ Robert Pohly
         

     

     

     

     

     

     

     

     

     

     

     

     

     

     
     

    Exhibit B

    Samlyn Capital, LLC is the relevant entity for which Robert Pohly may be considered a control person.

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $CRVS alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CRVS

    DatePrice TargetRatingAnalyst
    1/2/2025$11.00Buy
    H.C. Wainwright
    8/18/2023$7.00Outperform
    Oppenheimer
    12/3/2021$5.00 → $8.00Overweight
    Cantor Fitzgerald
    12/1/2021$8.00Buy
    Jefferies
    8/3/2021$4.00 → $3.50Neutral
    Mizuho
    7/16/2021$9.50 → $6.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $CRVS
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

      Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3 demonstrates clinically meaningful reduction in itch as early as day 8 Enrollment initiated in extension cohort study exploring the same cohort 3 dose (200 mg BID) for a longer 8-week treatment period SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patient

      6/4/25 7:00:00 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference

      SOUTH SAN FRANCISCO, Calif., May 28, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that members of its leadership team will conduct one-on-one meetings with investors and present a corporate overview at the 2025 Jefferies Global Healthcare Conference, which is being held in New York, NY. The presentation will be on Thursday, June 5 from 9:20-9:50 am ET. A webcast of the presentation will be available live and for 90 days following the event. The webcast may be accessed via the investor relations section of the Corvus website. About Corvus PharmaceuticalsCorvus Pharmaceuticals is a clinical-stage biopharmac

      5/28/25 4:01:00 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

      Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Phase 3 registrational clinical trial of soquelitinib in peripheral T cell lymphoma (PTCL) enrolling with multiple clinical sites open Early exercise of common stock warrants by stockholders providing cash proceeds of approximately $31.3 million Soquelitinib data to be highlighted on conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutica

      5/8/25 4:02:00 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVS
    Financials

    Live finance-specific insights

    See more
    • Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results

      Soquelitinib data from cohorts 1-3 of atopic dermatitis Phase 1 clinical trial demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Phase 3 registrational clinical trial of soquelitinib in peripheral T cell lymphoma (PTCL) enrolling with multiple clinical sites open Early exercise of common stock warrants by stockholders providing cash proceeds of approximately $31.3 million Soquelitinib data to be highlighted on conference call and webcast today at 4:30 p.m. ET / 1:30 p.m. PT SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutica

      5/8/25 4:02:00 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

      Data continue to demonstrate favorable safety and efficacy profile, including earlier and deeper responses in cohort 3 compared to cohorts 1-2 Data to be presented in an oral session and poster at the Society for Investigative Dermatology 2025 Annual Meeting Company to discuss data today on its first quarter 2025 business update conference call and webcast at 4:30 pm ET / 1:30 pm PT SOUTH SAN FRANCISCO, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate

      5/8/25 4:01:00 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025

      Data from Cohorts 1-3 of trial to be presented in an oral session and poster at the Society for Investigative Dermatology (SID) 2025 Annual Meeting Company to discuss data on its first quarter 2025 business update conference call and webcast scheduled for 4:30 pm ET / 1:30 pm PT on May 8, 2025 SOUTH SAN FRANCISCO, Calif., April 23, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced that new interim data from the randomized, double-blind, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis will be presented in an oral session and poster at the S

      4/23/25 4:08:12 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVS
    SEC Filings

    See more
    • Corvus Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Corvus Pharmaceuticals, Inc. (0001626971) (Filer)

      6/4/25 7:00:11 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Corvus Pharmaceuticals Inc.

      SCHEDULE 13G/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)

      5/15/25 3:34:17 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13D/A filed by Corvus Pharmaceuticals Inc.

      SCHEDULE 13D/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)

      5/14/25 8:49:03 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Corvus Pharmaceuticals Inc.

      SC 13G/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)

      8/1/24 9:18:47 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Corvus Pharmaceuticals Inc. (Amendment)

      SC 13G/A - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)

      5/13/24 4:52:14 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Corvus Pharmaceuticals Inc.

      SC 13G - Corvus Pharmaceuticals, Inc. (0001626971) (Subject)

      5/9/24 5:29:29 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVS
    Leadership Updates

    Live Leadership Updates

    See more

    $CRVS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors

      SOUTH SAN FRANCISCO, Calif., April 09, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, announced today that Richard van den Broek, managing partner at HSMR Advisors, has been appointed to the Company's board of directors. Mr. van den Broek has more than 30 years of experience in the life sciences industry as an investor, biotechnology equity research analyst and board member. "We're thrilled to welcome Richard to our board," said Richard A. Miller, M.D., chairman, president and chief executive officer of Corvus. "Richard has a proven track record in the biotechnology sector and a deep understanding of the global pharmaceutic

      4/9/25 4:01:54 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer

      BURLINGAME, Calif., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of Jeffrey Arcara as Chief Business Officer. Mr. Arcara, who is a proven leader with more than 30 years of commercial experience in the biopharmaceutical industry, will be responsible for leading corporate strategy, business development, portfolio strategy, and new product planning. "Corvus is leading the development of ITK inhibition as a platform opportunity across oncology and immune diseases. The addition of Jeff as chief business officer strengthens our ability to maximize the potential of our ITK programs, both

      2/6/24 4:05:00 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Corvus Pharmaceuticals Appoints Dr. James Rosenbaum Senior Vice President of Research

      BURLINGAME, Calif., July 21, 2022 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the appointment of James Rosenbaum, M.D. as Senior Vice President of Research, effective immediately. His initial focus will be to lead the development of CPI-818, the Company's ITK inhibitor, for the treatment of immune disorders such as T cell lymphomas, autoimmune and allergic diseases.  CPI-818 is currently being studied in a Phase 1/1b clinical trial for the treatment of T cell lymphomas, the results of which we believe could support advancing CPI-818 into a global Phase 2 trial. In addition, recent resea

      7/21/22 4:05:00 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Miller Richard A Md exercised 559,073 shares at a strike of $3.50, increasing direct ownership by 97% to 1,136,707 units (SEC Form 4)

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      5/9/25 4:09:21 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Van Den Broek Richard

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      4/9/25 5:26:56 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Van Den Broek Richard claimed ownership of 160,000 shares (SEC Form 3)

      3 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      4/9/25 5:26:25 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Jones William Benton bought $34,624 worth of shares (20,000 units at $1.73), increasing direct ownership by 15% to 153,773 units (SEC Form 4)

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      5/7/24 5:06:34 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Miller Richard A Md bought $1,000,000 worth of shares (577,634 units at $1.73) (SEC Form 4)

      4 - Corvus Pharmaceuticals, Inc. (0001626971) (Issuer)

      5/7/24 5:05:52 PM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CRVS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on Corvus Pharmaceuticals with a new price target

      H.C. Wainwright initiated coverage of Corvus Pharmaceuticals with a rating of Buy and set a new price target of $11.00

      1/2/25 7:32:41 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Oppenheimer initiated coverage on Corvus Pharmaceuticals with a new price target

      Oppenheimer initiated coverage of Corvus Pharmaceuticals with a rating of Outperform and set a new price target of $7.00

      8/18/23 8:04:45 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald reiterated coverage on Corvus Pharmaceuticals with a new price target

      Cantor Fitzgerald reiterated coverage of Corvus Pharmaceuticals with a rating of Overweight and set a new price target of $8.00 from $5.00 previously

      12/3/21 9:11:26 AM ET
      $CRVS
      Biotechnology: Pharmaceutical Preparations
      Health Care